PREFER’s patient input to decision making under evaluation by EMA and EUnetHTA
At Clinigma®, we are always happy to follow the development of projects promoting patient engagement and the incorporation of the patients’ voices in drug development.
An interesting project you may have heard of is the Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project.
“Medical products are developed by pharma companies, approved by regulators, and assessed by health technology bodies. But in the end, the medicines and medical products are meant for patients.”
The PREFER project is a five year public-private collaborative research project that has been going on for a couple of years under the Innovative Medicines Initiative (IMI). The aim of the project is to establish recommendations to support the development of guidelines for industry, Regulatory Authorities and HTA bodies on how and when to use patient preferences as input in medical product decision making.
“Patient preferences reflect which aspects of health treatments matter to patients individually and why patients choose a particular treatment (medicine or medical device) over others.”
The PREFER project builds its recommendations on patient preference studies in both academic and industry settings providing a better understanding of best-practice approaches as well as showing how patient preference studies can give valuable information to support regulatory decision making.
Status is that the PREFER project is now in the process of getting the EMA and EUnetHTA to assess its framework to patient preference studies and issue a public qualification opinion on how useful the approach is. The final recommendations from the PREFER project are expected to be presented in the autumn of 2021.
Clinigma® will follow the development of the PREFER project and look forward to sharing more news on this project as well as on other initiatives with the aim to advance patient engagement in drug development.
Do you want to read more about the PREFER project? Click here to visit their website.